Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2026-03-26 00:00:00 ET · period of report 2026-03-24 · accession 0001861477-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-26 | 2026-03-24 | ACAD | Thompson Elizabeth H.Z. | EVP, Head of Research, Dev | M - OptEx | — | +6,715 | 6,715 | New | — |
| D | 2026-03-26 | 2026-03-25 | ACAD | Thompson Elizabeth H.Z. | EVP, Head of Research, Dev | S - Sale+OE | $21.47 | -3,435 | 3,280 | -51% | -$73.7K |
| D | 2026-03-26 | 2026-03-24 | ACAD | Thompson Elizabeth H.Z. | EVP, Head of Research, Dev | M - OptEx | $0.00 | -6,715 | 20.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-24 | M | A | 6,715 | — | 6,715 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Common | Common Stock | 2026-03-25 | S | D | 3,435 | $21.47 | 3,280 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2026-03-24 | M | D | 6,715 | $0.00 | 20,146 | D | — · — to — | 6,715 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning March 24, 2026. |